Use of Kif13A and AP-1 Inhibitors for Inhibiting Melanogenesis

Abstract

The present invention relates to novel pharmaceutical or cosmetic compositions comprising at least one inhibitor of a sub-unit of AP-1 adaptor complex, of a kinesin interacting with AP-1, in particular Kif13A, or of the interaction between a sub-unit of AP-1 adaptor complex and said kinesin, as well as the use of same to manufacture a drug intended for the treatment of pigmentary disorders and as a depigmentation agent.

1 - 16 . (canceled) 
     
     
         17 . A pharmaceutical or cosmetic composition comprising at least one kinesin Kif13A inhibitor, an inhibitor of a sub-unit of AP-1 adaptor complex, and/or an inhibitor of the interaction between a sub-unit of AP-1 adaptor complex or the AP-1 complex and kinesin Kif13A. 
     
     
         18 . The composition of  claim 17 , wherein said inhibitor is a kinesin Kif13A inhibitor. 
     
     
         19 . The composition of  claim 17 , wherein said inhibitor is an inhibitor of a sub-unit of AP-1 adaptor complex. 
     
     
         20 . The composition of  claim 17 , wherein said inhibitor is an inhibitor of the interaction between a sub-unit of AP-1 adaptor complex or the AP-1 complex and kinesin Kif13A. 
     
     
         21 . The composition of  claim 17 , wherein said inhibitor is a small molecule, an aptamer, an antibody, a nucleic acid or a dominant negative peptide. 
     
     
         22 . The composition of  claim 21 , wherein said inhibitor is an aptamer, an antibody, a nucleic acid or a dominant negative peptide. 
     
     
         23 . The composition of  claim 17 , wherein said inhibitor is a nucleic acid comprising a sequence able to hybridize specifically with a gene or mRNA coding for a sub-unit of AP-1 adaptor complex or for kinesin Kif13A and to decrease or suppress the expression of said protein. 
     
     
         24 . The composition of  claim 23 , wherein said nucleic acid is an antisense oligonucleotide or a iRNA. 
     
     
         25 . The composition of  claim 23 , wherein said nucleic acid is a siRNA. 
     
     
         26 . The composition of  claim 23 , wherein said nucleic acid has a sequence of 15 to 50 nucleotides. 
     
     
         27 . The composition of  claim 23 , wherein said nucleic acid has a sequence of 15 to 30 nucleotides. 
     
     
         28 . The composition of  claim 23 , wherein said nucleic acid comprises a sequence selected from the group consisting of SEQ ID NO: 1, 2, 3, 4, 5, 6, 11, 2, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24. 
     
     
         29 . The composition of  claim 17 , wherein said composition further comprises one or more active substances selected from the group consisting of ellagic acid; arbutin; resorcinol; vitamin C; pantothenate; kojic acid; placental extracts; molecules interfering directly or indirectly with melanotropin (MSH), its receptor or adrenocorticotropic hormone (ACTH); polyols; vitamins; keratolytic and/or exfoliating agents; alpha-hydroxy acids; ascorbic acid; retinoic acid; retinaldehyde; retinol; palmitate, propionate; acetate; anti-glycation and/or antioxidant agents; anti-inflammatory agents; soothing agents and mixtures thereof; chemical or physical sun filters; deoxyribonucleic acids; and ribonucleic acids. 
     
     
         30 . The composition of  claim 29 , wherein said anti-glyation and/or antioxidant agents are tocopherol, thiotaurine, hypotaurine, aminoguanidine, thiamin pyrophosphate, pyridoxamine, lysine, histidine, arginine, phenylalanine, pyridoxine or adenosine triphosphate. 
     
     
         31 . The composition of  claim 17 , wherein said composition is a cosmetic composition. 
     
     
         32 . The composition of  claim 17 , wherein said composition is a pharmaceutical composition. 
     
     
         33 . A method for treating or preventing a pigmentary disorder in a subject comprising applying to the skin of the subject a pharmaceutical composition of  claim 17 . 
     
     
         34 . The method of  claim 33 , wherein the pigmentary disorder is hyperpigmentation.